Insulet Co. (NASDAQ:PODD) Shares Purchased by Integrated Wealth Concepts LLC

Integrated Wealth Concepts LLC increased its holdings in Insulet Co. (NASDAQ:PODD - Free Report) by 39.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,562 shares of the medical instruments supplier's stock after purchasing an additional 1,001 shares during the quarter. Integrated Wealth Concepts LLC's holdings in Insulet were worth $930,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Horizon Investments LLC raised its stake in shares of Insulet by 3.1% during the 4th quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier's stock worth $362,000 after buying an additional 42 shares during the period. Nisa Investment Advisors LLC lifted its holdings in Insulet by 1.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier's stock valued at $1,146,000 after purchasing an additional 43 shares in the last quarter. Graypoint LLC grew its position in shares of Insulet by 5.3% in the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier's stock valued at $243,000 after purchasing an additional 47 shares during the period. Wilmington Savings Fund Society FSB increased its stake in shares of Insulet by 9.6% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier's stock worth $140,000 after purchasing an additional 47 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. raised its position in shares of Insulet by 2.3% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier's stock worth $552,000 after purchasing an additional 48 shares during the last quarter.

Insulet Trading Up 2.7 %

Shares of NASDAQ PODD traded up $6.76 during mid-day trading on Friday, reaching $257.01. 838,676 shares of the company's stock were exchanged, compared to its average volume of 717,346. The company's 50-day moving average is $257.51 and its 200-day moving average is $262.48. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The firm has a market capitalization of $18.05 billion, a price-to-earnings ratio of 44.39, a PEG ratio of 3.62 and a beta of 1.30. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Analysts expect that Insulet Co. will post 3.92 EPS for the current fiscal year.

Analysts Set New Price Targets

PODD has been the subject of several research reports. Wells Fargo & Company set a $322.00 price objective on Insulet in a research note on Monday, April 28th. Citigroup raised their price objective on Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a report on Friday, February 21st. Barclays lifted their target price on shares of Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a research note on Wednesday. Canaccord Genuity Group increased their target price on shares of Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Finally, Piper Sandler boosted their price target on shares of Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $293.94.

Insider Activity at Insulet

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the transaction, the director now directly owns 3,231 shares in the company, valued at $888,525. This trade represents a 36.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.47% of the stock is owned by insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.